Drug intelligence / Profile preview

durvalumab + polyICLC + tremelimumab

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intratumoral, Intravenous

Overview

A combination immunotherapy regimen consisting of durvalumab (anti-PD-L1 antibody), tremelimumab (anti-CTLA-4 antibody), and polyICLC (toll-like receptor 3 agonist). This combination approach aims to enhance anti-tumor immune responses through complementary mechanisms: blocking immune checkpoints with durvalumab and tremelimumab while stimulating immune activation with polyICLC, which is typically administered intratumorally to create an "in situ vaccination" effect.

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TLR3 (Toll-like receptor 3)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on durvalumab + polyICLC + tremelimumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on durvalumab + polyICLC + tremelimumab.

Explore the full profile